

A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma

Benjamin Ory, Matthew R. Ramsey, Catherine Wilson, Douangsone D. Vadysirisack, Nicole Forster, James W. Rocco, S. Michael Rothenberg, Leif W. Ellisen

J Clin Invest. 2014;**124**(3):1418-1418. <https://doi.org/10.1172/JCI75406>.

Corrigendum

Original citation: *J. Clin. Invest.* 2011;121(2):809–820. doi:10.1172/JCI43897. Citation for this corrigendum: *J. Clin. Invest.* 2014;124(3):1418. doi:10.1172/JCI75406. During the assembly of Figure 1A of this manuscript, incorrect β -tubulin immunoblots were inadvertently included. The authors were unable to retrieve the original raw data; however, results from a replicate experiment are shown in the corrected figure panel below. The authors regret the error.

Find the latest version:

<https://jci.me/75406/pdf>





Corrigendum

A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma


Benjamin Ory, Matthew R. Ramsey, Catherine Wilson, Douangson D. Vadysirisack, Nicole Forster, James W. Rocco, S. Michael Rothenberg, and Leif W. Ellisen

Original citation: *J Clin Invest.* 2011;121(2):809–820. doi:10.1172/JCI43897.

Citation for this corrigendum: *J Clin Invest.* 2014;124(3):1418. doi:10.1172/JCI75406.

During the assembly of Figure 1A of this manuscript, incorrect β -tubulin immunoblots were inadvertently included. The authors were unable to retrieve the original raw data; however, results from a replicate experiment are shown in the corrected figure panel below.

The authors regret the error.



Corrigendum

RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer

Violeta Serra,¹ Pieter J.A. Eichhorn,² Celina García-García,¹ Yasir H. Ibrahim,¹ Ludmila Prudkin,³ Gertrudis Sánchez,³ Olga Rodríguez,¹ Pilar Antón,¹ Josep-Lluís Parra,⁴ Sara Marlow,⁵ Maurizio Scaltriti,⁶ José Pérez-García,⁷ Aleix Prat,⁸ Joaquín Arribas,^{4,9} William C. Hahn,^{10,11} So Young Kim,¹² and José Baselga^{1,6}

¹Experimental Therapeutics, Vall d'Hebron Institute of Oncology, Barcelona, Spain. ²Cancer Science Institute of Singapore, National University of Singapore, Singapore. ³Molecular Pathology and ⁴Growth Factors Groups, Vall d'Hebron Institute of Oncology, Barcelona, Spain. ⁵Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA. ⁶Human Oncology and Pathogenesis Program and Memorial Sloan-Kettering Cancer Center, New York, New York, USA. ⁷Breast Cancer and Melanoma Group and ⁸Translational Genomics Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain. ⁹Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain. ¹⁰Center for Cancer Genome Discovery, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA. ¹¹Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA. ¹²Department of Molecular Genetics and Microbiology, Duke RNAi Screening Facility, Duke University Medical Center, Durham, North Carolina, USA.

Original citation: *J Clin Invest.* 2013;123(6):2551–2563. doi:10.1172/JCI66343.

Citation for this corrigendum: *J Clin Invest.* 2014;124(3):1418. doi:10.1172/JCI75534.

The affiliation for Joaquín Arribas was incorrect. The correct affiliation list is above.

The authors regret the error.